Can Indian Pharma Survive Trump's 100% Tariff Threat on Generics?

Trump's tariff on Indian pharma is back in focus. Indian pharma stocks fell for a second day in a row. The reason is a new tariff threat from Donald Trump on generic medicines. The industry says it did not see this coming. The Nifty Pharma index slid nearly 2%. Sun Pharma, Cipla and Dr Reddy's all traded lower.

Why the nerves? Trump made the call in a social media post. The formal order with the fine print was not out yet. So traders were left to price in doubt, not clear rules.

What Trump actually said

This is not a flat, one-time tariff. It is a staged plan. The goal is to pull generic drug making onto US soil. Generic imports stay tax-free for two years. After that, the rate jumps hard.

Trump said the delay was meant to bring generic drug making back to America. Firms that skip building local plants will pay the price. Until now, generics had dodged his trade war. An April 2026 order had put tariffs of up to 100% on branded drugs. But it left generics out. This move closes that gap.

One legal point matters here. The Supreme Court threw out Trump's broad "reciprocal" tariffs in February 2026. Those leaned on emergency powers. But pharma tariffs use a different law, Section 232, which the court left alone. So this threat stands on firmer ground than the tariffs that were struck down.

Why India has so much at stake

The stakes go well beyond a few results. India is the top source of generic drugs for the US. In 2024, drugs from India filled more than half of all US scripts for birth control, anti-depressants and blood pressure.

India is called the "pharmacy of the world" for a reason. It has the most US FDA-cleared plants outside America. Drugs are among India's top three exports to the US. They were worth about $10.5 billion in the year to March 2025, per official Indian data. Some trade groups cite about $9.7 billion for the 2025 calendar year. The two windows differ, but the scale stays close.

"It's not practical to move"

The industry's mood is shock, not calm. Mahesh Doshi of the Indian Drug Manufacturers Association called it very surprising news. His group speaks for over a thousand drug firms. He said none of them saw it coming.

The sharpest pushback came from Dr Reddy's. CEO Erez Israeli said moving to the US is not practical. Generics run on thin margins. A tariff this size cannot be absorbed, he said. So US prices would rise by about the size of the tariff. North America is about a third of the firm's sales. That is not a side market. He added that the firm will not do anything special for now. And a real shift could take four to seven years, not two.

Namit Joshi of the Pharmaceutical Export Promotion Council agreed. Two years is not enough to build a generic drug base from scratch. He flagged two gaps: a shortage of skilled staff, and the supply chains that feed raw drug inputs. A US plant would still need to buy those inputs from abroad.

Why analysts see a smaller hit

Not everyone sees a crisis. Trade think tank GTRI said the blow may be milder than the headline. Several Indian firms already run US plants. That gives them a head start. And even a 100% tariff would not wipe out India's price edge. Indian generics still cost far less than branded drugs. So much of the extra cost would fall on US insurers, hospitals and patients, not on Indian firms.

Where does GTRI see real strain? At the premium end. The most pressure should hit high-value generics and branded generics. There, making drugs in America could start to pay off. So it is the top slice of India's mix that is most at risk, not the whole business.

Vishal Manchanda of Systematix Group made a like point. Some firms may shift only their higher-margin drugs to the US. They could do this through tech transfers or contract deals, not full rebuilds. The other route is to spread out: lean less on the US and grow in new markets.

The trade deal and talks

The move fits Trump's carrot-and-stick style with India. He uses tariff threats as leverage while a deal stays unsigned. An interim India-US trade pact from February 2026 had promised "negotiated outcomes" on generic drugs and inputs. But that deal is not final yet.

US Secretary of State Marco Rubio met India's foreign minister S. Jaishankar in Manila on 23 July. The tariff did not come up in that talk. Rubio said he would expect India to be worried. But they had not raised it with him. The Indian Pharmaceutical Alliance said it will keep talking to Washington to find a fix that helps patients on both sides.

What it means for pharma stocks

There is a real wrinkle for investors. The tariff would not bite until 2028, near the end of Trump's term. So why sink heavy, long-term money into US plants now? The rules may not even last that long.

For now, the drop in pharma stocks is about mood and headline risk. It is not confirmed damage to earnings. The fine print is still pending. A wider tariff fight runs on other fronts. And India-US trade talks are still open. Traders watching Nifty Pharma should treat the next few weeks of trade-talk news as the real signal, not just the tariff number.

Sources: reported statements from Dr Reddy's, the Indian Drug Manufacturers Association, the Pharmaceutical Export Promotion Council and the Indian Pharmaceutical Alliance; analysis from GTRI and Systematix Group; and India's official commerce trade data, as carried by news wire reports (July 2026).